Ontario provides access to Biktarvy for treatment of HIV
“To help support the long-term health of people living with HIV, it is ideal that treatment regimens deliver both durable viral suppression and a demonstrated tolerability profile,” said
Superluminal Medicines secured $120m in a Series A funding round to advance the development of its assets into clinical trials.
Givosiran, which has been developed to be subcutaneously administered, targets aminolevulinic acid synthase 1 (ALAS1). According to Alnylam, monthly administration of the investigational RNAi therapeutic can potentially reduce
The collaboration includes the availability of HCL’s Faster Intelligent Trials (FIT) Solution using Oracle Health Sciences Mobile Health (mHealth) Connector Cloud Service (Oracle mHealth Cloud). HCL’s FIT solution
The study has achieved its co-primary endpoint of investigator-assessed progression-free survival (PFS). Roche’s combination of Tecentriq plus platinum-based chemotherapy demonstrated a statistically significant reduction in the risk of